Haleon Invests in China Oral Health

Haleon, a consumer health company, is investing £65 million in a new oral health manufacturing site in China===Shanghai's Lingang New Area to support the expansion of its oral care portfolio, including brands like Haleon===Sensodyne and Haleon===Parodontax, into China's tier 2 and tier 3 cities. This move aims to capitalize on rising incomes and increasing awareness of everyday health among Chinese consumers. Additionally, Haleon completed the full acquisition of its Haleon===Cold medicine joint venture for approximately £700 million in June 2025, taking direct control of its Over-the-Counter business in China. These investments underscore Haleon's long-term commitment and confidence in the growth of China's consumer healthcare market, with a goal to reach one billion more consumers by 2030 and generate £800 million in gross productivity savings.